SNPMiner Trials (Home Page)
Report for SNP rs2516513
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study
Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.
NCT04415918 Clostridium Difficile Infection Recurrence Drug: Bezlotoxumab Injection MeSH:Infection Clostridium Infections Enterocolitis, Pseudomembranous Recurrence
Explore if genetic variants (SNP rs2516513 on xMHC, SNP genotype on IL-8 gene promotor, SNP rs2243250 IL-4 gene,….)
Primary Outcomes
Description: Documentation of recurrent CDI infection
Measure: The proportion of patients with recurrent CDIs within 12 weeks of initial cure compared with historical group of patients selected with same inclusion/exclusion criteria (same center within 3 years of the start date of the study). Time: 12 weeksSecondary Outcomes
Description: Pharmacoeconomic analysis
Measure: Determine if bezlotoxumab infusion add-on treatment is cost saving in patients with malignancies in terms of preventing CDI recurrence. Time: 12 weeksOther Outcomes
Description: Genetic analysis is performed to describe gene type
Measure: Explore if genetic variants (SNP rs2516513 on xMHC, SNP genotype on IL-8 gene promotor, SNP rs2243250 IL-4 gene,….) are associated with increased recurrence of CDI in this patient population. Time: 12 weeks